Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 7,630 matching trials from the live ClinicalTrials.gov search.

Filters: Jacksonville, Florida Clear all

Conditions: Human Immunodeficiency Virus Transmission, Sexually Transmitted Diseases
Interventions: HIV Prevention Decision Support Tool (DST), Standard Counseling; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer, Metastases
Interventions: Ixabepilone; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 17
States / cities: La Verne, California • Meriden, Connecticut • Jacksonville, Florida + 14 more

Conditions: Breast Cancer
Interventions: Tesetaxel and Capecitabine, Capecitabine; Drug
Lead sponsor: Odonate Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 90
States / cities: Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more

Conditions: Epilepsy
Interventions: GW273225; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions: Placebo, SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 37
States / cities: Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more

Conditions: Obesity, Menopause
Interventions: semaglutide or tirzepatide, Lifestyle modification intervention; Drug · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 46 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 40
States / cities: Birmingham, Alabama • La Jolla, California • San Mateo, California + 37 more

Conditions: Immune Thrombocytopenia
Interventions: Lusutrombopag; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more

Conditions: Acute Ischemic Stroke
Interventions: NeVa Stent Retrievers; Device
Lead sponsor: Vesalio; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Thousand Oaks, California • Jacksonville, Florida • Marietta, Georgia + 4 more

Conditions: Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: Core size Xience Prime, Xience Prime Long Lesion (LL); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 56
States / cities: Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more

Conditions: Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
Interventions: Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening); Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 79 Years
Enrollment: 6,466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Venous Thromboembolism, Cancer
Interventions: Semuloparin sodium, Placebo (for semuloparin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 3,212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 48
States / cities: Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more

Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions: TG4050; Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Crohn Disease
Interventions: Etrolizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 59
States / cities: Arcadia, California • La Jolla, California • Long Beach, California + 51 more

Conditions: Lymphoma, Neuroblastoma, Sarcoma
Interventions: computed tomography, magnetic resonance imaging, positron emission tomography; Procedure
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: Up to 21 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 14 more

Conditions: Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions: Transcutaneous nerve stimulation location 1; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 55 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Liver Transplant Disorder, Reperfusion Injury
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Carcinoma, Renal Cell
Interventions: Sorafenib (Nexavar, BAY43-9006); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Maywood, Illinois + 4 more

Conditions: HIV/AIDS, Sexually Transmitted Infections
Interventions: RESPECT-2 Counseling; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 5,012 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Conditions: Cystitis, Interstitial
Interventions: Tanezumab, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 122
States / cities: Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more

Conditions: Prostate Cancer
Interventions: Ipilimumab, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 837 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 42
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: HIV Infections
Interventions: Videx EC, Epivir, Sustiva; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 46
States / cities: Little Rock, Arkansas • Beverly Hills, California • Fountain Valley, California + 43 more

Conditions: Cystic Fibrosis
Interventions: Sitagliptin; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 20 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Search by objective public record fields.

The OPENS Trial: Offering Women PrEP (Aim 1)

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study

SPIRIT PRIME Clinical Trial

Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma

Non-invasive Nerve Stimulation for PTSD and Sleep

Cardiac Strain Using Speckle Tracking Echocardiography During Orthotopic Liver Transplantation

Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.

A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis